A Phase 1/2 interventional study of Emibetuzumab and Ramucirumab in Advanced Cancer, Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, sponsored by Eli Lilly and Company. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-19.
Sponsored by Eli Lilly and Company · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 566 studies in Liver Neoplasms with a site in United States — 82 open to participants now, 122 under way, 6 of them phase 3. Liver Neoplasms · United States.
Among the 566 studies in Liver Neoplasms with a site in United States, this one is the 95th largest by enrollment of the 433 interventional ones that give a count, is one of 20 that started in 2014, is one of 51 in phase 1/2, and was the 294th registered.
1,346 studies on the registry are indexed under Liver Neoplasms; 335 are open to participants now.
Browse Liver Neoplasms studies →82 of the 566 studies in Liver Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 12+
Varian, a Siemens Healthineers Company · Sites in United States
Ages 21+
University of Oklahoma · Sites in United States
Ages 18+
Melissa Lumish · Sites in United States
Ages 18+
Northwestern University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 243 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 69 (28%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
566 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 189 · Phase 2 178 · Phase 3 29 · Phase 4 13
First in 1992; this study’s year is marked. 20 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 97 is above the median of 47 across 928 interventional studies indexed under Liver Neoplasms.
Median enrollment 30 across the 433 interventional studies, 143 across the 111 observational. Of the 398 that completed or were terminated, 144 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
166 of 566 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 5 studies filed under Liver Neoplasms — fewer than ten, so there is no comparison to draw.
40 of the studies in Liver Neoplasms with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02523443Phase 3Memorial Sloan Kettering Cancer CenterPatient Controlled Epidural Analgesia Versus Intravenous Patient Controlled Analgesia for Post-Operative Pain Control in Patients Undergoing Elective Liver Resection | 2027-08 |
| NCT00582647Memorial Sloan Kettering Cancer CenterCollection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract | 2026-12 |
| NCT07224464New Phase Ltd.The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia. | 2026-12 |
| NCT07044362Case Comprehensive Cancer CenterHistotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis | 2026-12-01 |
| NCT06852820Melissa Lumish68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC) | 2026-12-01 |
Add all 40 to your calendar (.ics) → With an account.
Among the 566 studies in Liver Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to find a recommended schedule and dose range for Emibetuzumab when given with ramucirumab that may be safely given to participants with cancer. In Part A of this study, escalating doses of Emibetuzumab will be given in combination with a fixed dose of ramucirumab to evaluate the safety of the combination. After a recommended schedule and dose range of Emibetuzumab and ramucirumab has been established, Part B of the study will confirm safety and to see how well certain tumors respond to the combination of study drugs. The average amount of time on study is expected to be about 6 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must have histological or cytological confirmed diagnosis of the following tumor types that is advanced and/or cancer and must be, in the judgment of the investigator, an appropriate participant for experimental therapy
Exclusion Criteria:
For Part B4 (non-small cell lung cancer) only:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A: Dose escalation (750mg, 2000mg) of Emibetuzumab administered intravenously (IV), on days 1 and 15 every 28 day cycle in combination with a fixed dose of 8mg/kg ramucirumab administered IV on Days 1 and 15 every 28 day cycle.
Drug: Emibetuzumab · Drug: Ramucirumab
Part B: Recommended 750mg Emibetuzumab dose from Part A to be administered IV, on days 1 and 15 every 28 day cycle in combination with a fixed dose of 8mg/kg ramucirumab administered IV on Days 1 and 15 every 28 day cycle.
Drug: Emibetuzumab · Drug: Ramucirumab
Administered Intravenously (IV)
Also known as: LY2875358
Administered Intravenously (IV)
Also known as: LY3009806, IMC-1121B
Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)
DLT is defined as an adverse event during Cycle1 that is possibly, probably, or definitely related to treatment with Emibetuzumab in combination with fixed regimen of Ramucirumab \& fulfills any 1 of the following criterion using NCI CTCAE Version 4.03: Grade 3 non-hematological toxicity. Exceptions will be made for:Nausea, vomiting, diarrhea, constipation, or skin rash that persists for ≤3 days following appropriate supportive care intervention. Grade 3 hypertension in which systolic BP ≥160 mmHg and/or diastolic BP ≥100 mmHg persist \<7 days after intensified antihypertensive therapy is initiated. Grade 4 hematological toxicity of ≥7 days duration. ≥Grade 3 thrombocytopenia with ≥Grade 2 bleeding. Any febrile neutropenia. Any other significant toxicity deemed by the primary investigator \& Lilly clinical research personnel to be dose-limiting (eg, any toxicity that is possibly related to the study medication that requires the withdrawal of participant from study Cycle1).
Time frame: Baseline through Cycle 1 (28 day cycle)
Part B: Percentage of Participants Who Exhibit Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)]
ORR is the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
Time frame: Baseline through Measured Progressive Disease or Death (Up to 17 months)
Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Emibetuzumab
Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Emibetuzumab.
Time frame: Cycle 1: Day1 Predose, End of infusion, 3 Hours (h), 5h, 8h, 21h, 168h, 334h, 335h and 336h Post dose
Part B: Percentage of Participants Who Exhibit Stable Disease (SD) or Confirmed Response (CR) or Partial Response (PR) (Disease Control Rate [DCR])
DCR is the proportion of participants who exhibit a SD or confirmed CR or PR relative to baseline. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. Progressive disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
Time frame: Baseline through Measured Progressive Disease (Up to 17 months)
Part B: Progression Free Survival (PFS)
PFS was defined as the time from the date of first dose of study drug until first observation of objective (radiographically documented) PD as defined by RECIST v1.1 or death from any cause, whichever comes first. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
Time frame: Baseline to Measured Progressive Disease or Death (Up to 17 Months)
Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) From Time Zero to Tlast of Emibetuzumab
Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) from time zero to tlast of Emibetuzumab.
Time frame: Cycle 1: Day1 Predose, End of infusion, 3 Hours (h), 5h, 8h, 21h, 168h, 334h, 335h and 336h Post dose
Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Ramucirumab
Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Ramucirumab.
Time frame: Cycle 1: Day1 Predose, End of infusion, 3 Hours (h), 5h, 8h, 21h, 168h and 336h Post dose
Number of Participants With Treatment Emergent Anti-Emibetuzumab Antibodies
Participants were considered as treatment-emergent anti drug antibodies (TE ADA) positive if there is a ≥4-fold increase from baseline when ADAs were detected at baseline. If no ADAs were detected at baseline, TE ADA were defined as those with a titer 2 fold (1 dilution) greater than the minimum required dilution (MRD) of the screening assay (1:4 for anti-emibetuzumab antibodies).
Time frame: Baseline through 46 Months
Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of Ramucirumab
Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of Ramucirumab.
Time frame: Cycle 1: Day1 Predose, End of infusion, 3 Hours (h), 5h, 8h, 21h, 168h and 336h Post dose
Number of Participants With Treatment Emergent Anti-Ramucirumab Antibodies
Participants were considered as treatment-emergent anti drug antibodies (TE ADA) positive if there is a ≥4-fold increase from baseline when ADAs were detected at baseline. If no ADAs were detected at baseline, TE ADA were defined as those with a titer 2 fold (1 dilution) greater than the minimum required dilution (MRD) of the screening assay (1:10 for anti-ramucirumab antibodies).
Time frame: Baseline through 46 Months
Part A: Completers are those who have completed one cycle of treatment. Part B: Completers are those who 1)Have measurable disease at baseline and at least one post-baseline tumor assessment; and 2) Were treated until PD or death, or discontinued due to an AE and completed the required follow-up.
| Milestone | Part A - 750 mg Emibetuzumab | Part A - 2000 mg Emibetuzumab | Part B - Gastric | Part B - HCC | Part B - RCC | Part B - NSCLC |
|---|---|---|---|---|---|---|
| Started | 3 | 3 | 16 | 45 | 15 | 15 |
| Received at least one dose of study drug | 3 | 3 | 16 | 45 | 15 | 15 |
| Completed | 3 | 3 | 13 | 39 | 12 | 13 |
| Not completed | 0 | 0 | 3 | 6 | 3 | 2 |
| Withdrew: Death | 0 | 0 | 1 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 2 | 2 |
| Withdrew: Clinical progression | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: No post-baseline tumor assesment | 0 | 0 | 1 | 2 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 1 | 0 | 0 |
DLT is defined as an adverse event during Cycle1 that is possibly, probably, or definitely related to treatment with Emibetuzumab in combination with fixed regimen of Ramucirumab \& fulfills any 1 of the following criterion using NCI CTCAE Version 4.03: Grade 3 non-hematological toxicity. Exceptions will be made for:Nausea, vomiting, diarrhea, constipation, or skin rash that persists for ≤3 days following appropriate supportive care intervention. Grade 3 hypertension in which systolic BP ≥160 mmHg and/or diastolic BP ≥100 mmHg persist \<7 days after intensified antihypertensive therapy is initiated. Grade 4 hematological toxicity of ≥7 days duration. ≥Grade 3 thrombocytopenia with ≥Grade 2 bleeding. Any febrile neutropenia. Any other significant toxicity deemed by the primary investigator \& Lilly clinical research personnel to be dose-limiting (eg, any toxicity that is possibly related to the study medication that requires the withdrawal of participant from study Cycle1).
| Participants | Part A - 750 mg Emibetuzumab | Part A - 2000 mg Emibetuzumab | Part B - Gastric | Part B - HCC | Part B - RCC | Part B - NSCLC |
|---|---|---|---|---|---|---|
| Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) | 0 | 0 | 0 | 0 | 0 | 0 |
ORR is the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR is defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
| percentage of participants | Part B - Gastric | Part B - HCC | Part B - RCC | Part B - NSCLC |
|---|---|---|---|---|
| Part B: Percentage of Participants Who Exhibit Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)] | 6.3 (0 to 30) | 6.7 (0 to 20) | 0 (0 to 20) | 6.7 (0 to 30) |
Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Emibetuzumab.
| Microgram per milliliter (µg/mL) | All Parts - 750 mg Emibetuzumab | All Parts - 2000 mg Emibetuzumab |
|---|---|---|
| Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Emibetuzumab | 210 ± 27 | 575 ± 33 |
DCR is the proportion of participants who exhibit a SD or confirmed CR or PR relative to baseline. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. Progressive disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
| percentage of participants | Part B - Gastric | Part B - HCC | Part B - RCC | Part B - NSCLC |
|---|---|---|---|---|
| Part B: Percentage of Participants Who Exhibit Stable Disease (SD) or Confirmed Response (CR) or Partial Response (PR) (Disease Control Rate [DCR]) | 50 (20 to 80) | 60 (40 to 70) | 46.7 (20 to 70) | 86.7 (60 to 100) |
PFS was defined as the time from the date of first dose of study drug until first observation of objective (radiographically documented) PD as defined by RECIST v1.1 or death from any cause, whichever comes first. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
| months | Part B - Gastric | Part B - HCC | Part B - RCC | Part B - NSCLC |
|---|---|---|---|---|
| Part B: Progression Free Survival (PFS) | 1.64 (1.35 to 4.60) | 5.42 (1.64 to 8.12) | 2.92 (1.18 to 7.39) | 6.57 (2.86 to 9.66) |
Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) from time zero to tlast of Emibetuzumab.
| Microgram * hour per milliliter(µg*h/mL) | All Parts - 750 mg Emibetuzumab | All Parts - 2000 mg Emibetuzumab |
|---|---|---|
| Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) From Time Zero to Tlast of Emibetuzumab | 29800 ± 26 | 86500 ± 25 |
Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Ramucirumab.
No measurements were reported for this outcome.
Participants were considered as treatment-emergent anti drug antibodies (TE ADA) positive if there is a ≥4-fold increase from baseline when ADAs were detected at baseline. If no ADAs were detected at baseline, TE ADA were defined as those with a titer 2 fold (1 dilution) greater than the minimum required dilution (MRD) of the screening assay (1:4 for anti-emibetuzumab antibodies).
| Participants | Part A - 750 mg Emibetuzumab | Part A - 2000 mg Emibetuzumab | Part B - Gastric | Part B - HCC | Part B - RCC | Part B - NSCLC |
|---|---|---|---|---|---|---|
| Number of Participants With Treatment Emergent Anti-Emibetuzumab Antibodies | 0 | 0 | 0 | 3 | 0 | 0 |
Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of Ramucirumab.
No measurements were reported for this outcome.
Participants were considered as treatment-emergent anti drug antibodies (TE ADA) positive if there is a ≥4-fold increase from baseline when ADAs were detected at baseline. If no ADAs were detected at baseline, TE ADA were defined as those with a titer 2 fold (1 dilution) greater than the minimum required dilution (MRD) of the screening assay (1:10 for anti-ramucirumab antibodies).
| Participants | Part A - 750 mg Emibetuzumab | Part A - 2000 mg Emibetuzumab | Part B - Gastric | Part B - HCC | Part B - RCC | Part B - NSCLC |
|---|---|---|---|---|---|---|
| Number of Participants With Treatment Emergent Anti-Ramucirumab Antibodies | 1 | 0 | 0 | 4 | 1 | 0 |
Collected over Up to 46 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A - 750 mg Emibetuzumab | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Part A - 2000 mg Emibetuzumab | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Part B - Gastric | 3/16 (18.8%) | 4/16 (25%) | 15/16 (93.8%) |
| Part B - HCC | 4/45 (8.9%) | 19/45 (42.2%) | 45/45 (100%) |
| Part B - RCC | 1/15 (6.7%) | 5/15 (33.3%) | 15/15 (100%) |
| Part B - NSCLC | 1/15 (6.7%) | 3/15 (20%) | 14/15 (93.3%) |
| Event | Part A - 750 mg Emibetuzumab | Part A - 2000 mg Emibetuzumab | Part B - Gastric | Part B - HCC | Part B - RCC | Part B - NSCLC |
|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 1/3 | 0/3 | 0/16 | 0/45 | 0/15 | 0/15 |
| OesophagitisGastrointestinal disorders | 1/3 | 0/3 | 0/16 | 0/45 | 0/15 | 0/15 |
| VomitingGastrointestinal disorders | 1/3 | 0/3 | 0/16 | 0/45 | 0/15 | 0/15 |
| PainGeneral disorders | 1/3 | 0/3 | 0/16 | 0/45 | 0/15 | 0/15 |
| PyrexiaGeneral disorders | 0/3 | 1/3 | 0/16 | 2/45 | 0/15 | 0/15 |
| PneumoniaInfections and infestations | 1/3 | 0/3 | 2/16 | 0/45 | 0/15 | 0/15 |
| Back painMusculoskeletal and connective tissue disorders | 0/3 | 1/3 | 0/16 | 0/45 | 0/15 | 0/15 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/3 | 1/3 | 0/16 | 0/45 | 1/15 | 1/15 |
| Pericardial effusionCardiac disorders | 0/3 | 0/3 | 0/16 | 0/45 | 1/15 | 1/15 |
| Abdominal distensionGastrointestinal disorders | 0/3 | 0/3 | 0/16 | 0/45 | 1/15 | 0/15 |
| Event | Part A - 750 mg Emibetuzumab | Part A - 2000 mg Emibetuzumab | Part B - Gastric | Part B - HCC | Part B - RCC | Part B - NSCLC |
|---|---|---|---|---|---|---|
| Oedema peripheralGeneral disorders | 3/3 | 0/3 | 6/16 | 26/45 | 5/15 | 5/15 |
| FatigueGeneral disorders | 1/3 | 1/3 | 11/16 | 25/45 | 6/15 | 9/15 |
| Decreased appetiteMetabolism and nutrition disorders | 2/3 | 0/3 | 8/16 | 11/45 | 3/15 | 3/15 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/3 | 1/3 | 2/16 | 12/45 | 8/15 | 2/15 |
| NauseaGastrointestinal disorders | 1/3 | 0/3 | 8/16 | 12/45 | 4/15 | 4/15 |
| VomitingGastrointestinal disorders | 1/3 | 0/3 | 6/16 | 7/45 | 1/15 | 5/15 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/3 | 0/3 | 0/16 | 7/45 | 1/15 | 0/15 |
| ConstipationGastrointestinal disorders | 0/3 | 0/3 | 5/16 | 12/45 | 3/15 | 5/15 |
| Gingival bleedingGastrointestinal disorders | 1/3 | 0/3 | 0/16 | 1/45 | 1/15 | 1/15 |
| Gingival swellingGastrointestinal disorders | 1/3 | 0/3 | 0/16 | 0/45 | 0/15 | 0/15 |
| Age, Continuous(years) | Part A - 750 mg Emibetuzumab | Part A - 2000 mg Emibetuzumab | Part B - Gastric | Part B - HCC | Part B - RCC | Part B - NSCLC | Total |
|---|---|---|---|---|---|---|---|
| Mean | 41.3 ± 20.6 | 62.0 ± 13.5 | 62.6 ± 9.1 | 63.4 ± 9.5 | 63.1 ± 10.1 | 59.9 ± 8.6 | 62.0 ± 10.4 |
| Sex: Female, Male(Participants) | Part A - 750 mg Emibetuzumab | Part A - 2000 mg Emibetuzumab | Part B - Gastric | Part B - HCC | Part B - RCC | Part B - NSCLC | Total |
|---|---|---|---|---|---|---|---|
| Female | 3 | 0 | 4 | 11 | 3 | 6 | 27 |
| Male | 0 | 3 | 12 | 34 | 12 | 9 | 70 |
| Ethnicity (NIH/OMB)(Participants) | Part A - 750 mg Emibetuzumab | Part A - 2000 mg Emibetuzumab | Part B - Gastric | Part B - HCC | Part B - RCC | Part B - NSCLC | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 3 | 2 | 0 | 6 |
| Not Hispanic or Latino | 3 | 3 | 15 | 36 | 13 | 14 | 84 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part A - 750 mg Emibetuzumab | Part A - 2000 mg Emibetuzumab | Part B - Gastric | Part B - HCC | Part B - RCC | Part B - NSCLC | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Asian | 0 | 0 | 0 | 7 | 0 | 2 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 | 3 | 0 | 1 | 6 |
| White | 3 | 2 | 14 | 32 | 14 | 11 | 76 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Part A - 750 mg Emibetuzumab | Part A - 2000 mg Emibetuzumab | Part B - Gastric | Part B - HCC | Part B - RCC | Part B - NSCLC | Total |
|---|---|---|---|---|---|---|---|
| United States | 3 | 3 | 16 | 45 | 15 | 15 | 97 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2014 to primary completion in Dec 2017, 44 months.
Results were first posted in Dec 2020, 3 years after primary completion. A results delay was requested in Nov 2018.
Of 33 phase 1/2 interventional studies under Liver Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 72. This study's 44 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Emibetuzumab · Ramucirumab